Effect of third- and fourth-line systemic therapies for metastatic renal cell carcinoma

Data on the outcomes of third- or fourth-line therapy for metastatic renal cell carcinoma (mRCC) are limited. The aim of our study was to evaluate the efficacy of therapy beyond the second line. We retrospectively analysed data of mRCC patients who underwent systemic therapy at Yamagata University H...

Descripción completa

Detalles Bibliográficos
Autores principales: Naito, Sei, Ichiyanagi, Osamu, Kato, Tomoyuki, Kanno, Hidenori, Narisawa, Takafumi, Kurokawa, Masayuki, Ushijima, Masaki, Ozawa, Michinobu, Yagi, Mayu, Kurota, Yuta, Fukuhara, Hiroki, Yamagishi, Atsushi, Sakurai, Toshihiko, Nishida, Hayato, Kawazoe, Hisashi, Yamanobe, Takuya, Tsuchiya, Norihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6820538/
https://www.ncbi.nlm.nih.gov/pubmed/31664053
http://dx.doi.org/10.1038/s41598-019-51305-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6820538/
https://www.ncbi.nlm.nih.gov/pubmed/31664053
http://dx.doi.org/10.1038/s41598-019-51305-7

Ejemplares similares